CELL THERAPY CONSISTING OF PRO-INFLAMMATORY MONOCYTE-DERIVED DENDRITIC CELLS (MODCS), ISOLATED FROM AN ALLOGENEIC HUMAN HEALTHY BLOOD DONOR AND EX-VIVOSTIMULATED WITH RESIQUIMOD (R848), POLYINOSINIC-POLYCYTIDYLIC ACID (POLY(I:C)) AND INTERFERON GAMMA (IF
Injection of these cells in the patient's tumor generates an inflammatory response which in turns leads to tumor-specific activation of the patient's cytotoxic T cells
